Dr. Michael Gerdis, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 397
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NY license 185309 -
Internal Medicine Physician
NY license 185309
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Mount Sinai School of Medicine of New York University (30 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 397
- Services billed
- 1,023
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 256 | 206 |
| Established patient office or other outpatient visit, 30-39 minutes | 255 | 181 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 131 | 131 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 69 | 68 |
| New patient office or other outpatient visit, 45-59 minutes | 53 | 53 |
| Established patient office or other outpatient visit, 20-29 minutes | 42 | 40 |
| Biopsy of large bowel using a flexible endoscope | 35 | 35 |
| Diagnostic exam of large bowel using a flexible endoscope | 24 | 24 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | 15 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $1,869,428 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A phase 3 study to evaluate the efficacy immunogenicity and safety of respiratory syncytial virus rsv prefusion f subunit vaccine in adults
Pfizer Inc. - A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoa…
Novartis Pharmaceuticals Corporation - A phase 3 study to evaluate the safety tolerability and immunogenicity of a respiratory syncytial virus rsv prefusion f subunit vaccine in adults 60 years of age and older
Pfizer Inc. - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A phase 3 randomized doubleblind placebocontrolled clinical study evaluating the safety tolerability immunogenicity and efficacy of a variantadapted BNT162B2 vaccine in healthy participants 50 through 64 years of age
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.